Raf inhibitor LGX 818, Purity ≥98%

Synonym: Encorafenib; LGX818; 1269440-17-6; LGX-818; Braftovi; NVP-LGX818-NXA; Encorafenib (LGX818); Raf inhibitor

Product Size

5 mg; 10 mg; 25 mg; 50 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

LGX 818, soluble in DMSO and ethanol and insoluble in water, blocks a MAPK/ERK signaling pathway. It targets BRAF V600E.

Molecular Weight

540.01

Molecular Formula

C₂₂H₂₇ClFN₇O₄S

Targets

BRAF V600E: 4 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 93 mg/mL (172.22 mM); Water: Insoluble; Ethanol: 93 mg/mL (172.22 mM)

Identity

Confirmed by NMR/HPLC/MS.

Stability

The product is stable for three years when stored at the recommended temperature in lyophilized powder.

Applications

LGX 818 can be used to inhibit BRAF and study its therapeutic effects on melanoma.

Storage

Store at -20ºC.